(Q38953228)

English

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

scientific article published on 16 February 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (English)

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Evandro de Azambuja

6

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

11

object named as

Jose Baselga

1 reference

Europe PubMed Central

25 May 2018

10

object named as

Luca Gianni

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

8

object named as

Michael Untch

1 reference

Europe PubMed Central

25 May 2018

17

object named as

Mitch Dowsett

1 reference

Europe PubMed Central

25 May 2018

Aron Goldhirsch

5

object named as

Aron Goldhirsch

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

4

object named as

Marion Procter

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Herceptin Adjuvant (HERA) Trial Study Team

19

object named as

Herceptin Adjuvant (HERA) Trial Study Team

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Christian Jackisch

18

object named as

Christian Jackisch

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

author name string

David Cameron

1

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Martine J Piccart-Gebhart

2

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Richard D Gelber

3

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Gilberto Castro

7

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Ian Smith

9

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Nedal Al-Sakaff

12

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Sabine Lauer

13

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Eleanor McFadden

14

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Brian Leyland-Jones

15

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Richard Bell

16

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

language of work or name

0 references

publication date

17 February 2017

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

389

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

10075

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

1195-1205

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

The immune system and response to HER2-targeted treatment in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

17 June 2018

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

21 August 2018

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

21 August 2018

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

21 August 2018

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

21 August 2018

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5465633

21 August 2018

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2932616-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)32616-2

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

1 reference

Europe PubMed Central

25 May 2018

http://europepmc.org/abstract/PMC/5465633

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38953228&oldid=2117040767"